Hyperkalemia Market to Register Sustainable Growth During the Forecast Period – DelveInsight | Key Companies – Ardelyx, Vifor Pharma, AstraZeneca, Zeria Pharmaceutical, and others

August 12 22:17 2022
Hyperkalemia Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - Ardelyx, Vifor Pharma, AstraZeneca, Zeria Pharmaceutical, and others
Delveinsight Business Research LLP

DelveInsight’s “Hyperkalemia Market” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Hyperkalemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hyperkalemia: An Overview

Hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.

Risk factors for hyperkalemia include several conditions such as chronic kidney disease, diabetes, congestive heart failure and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.

Hyperkalemia Market Key Facts

  • According to the National Kidney Foundation, the prevalence and incidence of Hyperkalemia have been estimated to be 2-3% in the general population and about 1-10% among hospitalized patients. People with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines (RAASi) have an estimated 2–3 times higher risk for hyperkalemia. More than half of pre-dialysis CKD patients are at risk of developing Hyperkalemia.

  • In a study conducted by Betts et al. (2018), it was estimated that the annual prevalence of hyperkalemia was 1.57% in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes, and hypertension. Among patients with CKD and/or heart failure, the 2014 annual prevalence was 6.35%.

Hyperkalemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hyperkalemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Hyperkalemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Hyperkalemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Hyperkalemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperkalemia market or expected to get launched during the study period. The analysis covers Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hyperkalemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/hyperkalemia-market

Some of the key players in the Hyperkalemia market include:

  • Ardelyx

  • Vifor Pharma

  • AstraZeneca

  • Zeria Pharmaceutical

And others.

Hyperkalemia Therapies Covered in the report include:

  • Veltassa

  • Lokelma

  • RDX013

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/hyperkalemia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hyperkalemia Competitive Intelligence Analysis

4. Hyperkalemia Market Overview at a Glance

5. Hyperkalemia Disease Background and Overview

6. Hyperkalemia Patient Journey

7. Hyperkalemia Epidemiology and Patient Population

8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperkalemia Unmet Needs

10. Key Endpoints of Hyperkalemia Treatment

11. Hyperkalemia Marketed Products

12. Hyperkalemia Emerging Therapies

13. Hyperkalemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperkalemia Market Outlook (7 major markets)

16. Hyperkalemia Access and Reimbursement Overview

17. KOL Views on the Hyperkalemia Market.

18. Hyperkalemia Market Drivers

19. Hyperkalemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/hyperkalemia-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Report by DelveInsight

Subarachnoid Hemorrhage Market
“Subarachnoid Hemorrhage Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Subarachnoid Hemorrhage Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Subarachnoid Hemorrhage therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/